Metropolitan Life Insurance Co. NY maintained its stake in Loxo Oncology, Inc. (NASDAQ:LOXO) during the first quarter, Holdings Channel reports. The fund owned 10,559 shares of the biopharmaceutical company’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY’s holdings in Loxo Oncology were worth $444,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Legal & General Group Plc boosted its stake in Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 284 shares during the last quarter. Teachers Advisors LLC boosted its stake in Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 905 shares during the last quarter. American International Group Inc. boosted its stake in Loxo Oncology by 27.1% in the first quarter. American International Group Inc. now owns 9,749 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 2,081 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in Loxo Oncology by 9.7% in the first quarter. TIAA CREF Investment Management LLC now owns 40,772 shares of the biopharmaceutical company’s stock worth $1,716,000 after buying an additional 3,614 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Loxo Oncology by 33.3% in the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 3,875 shares during the last quarter.

Loxo Oncology, Inc. (NASDAQ LOXO) traded down 0.587% on Tuesday, reaching $73.625. 52,945 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $74.99 and a 200 day moving average price of $55.31. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $83.12. The stock’s market cap is $2.20 billion.

Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.99) by $0.15. During the same quarter last year, the firm earned ($0.77) EPS. Analysts forecast that Loxo Oncology, Inc. will post ($4.34) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/metropolitan-life-insurance-co-ny-holds-position-in-loxo-oncology-inc-loxo/1490925.html.

A number of research analysts recently weighed in on LOXO shares. BidaskClub downgraded shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. BTIG Research restated a “buy” rating and set a $75.00 price objective on shares of Loxo Oncology in a research report on Thursday, August 3rd. Zacks Investment Research upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price objective on the stock in a research report on Wednesday, August 9th. Stifel Nicolaus restated a “buy” rating and set a $94.00 price objective (up previously from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. Finally, Cowen and Company restated an “outperform” rating on shares of Loxo Oncology in a research report on Monday, June 5th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $79.67.

In other news, Director Keith T. Flaherty sold 7,250 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $45.09, for a total value of $326,902.50. Following the sale, the director now directly owns 27,141 shares of the company’s stock, valued at approximately $1,223,787.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 27.80% of the stock is owned by corporate insiders.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.